

# Sean J Mulvihill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11297435/publications.pdf>

Version: 2024-02-01

59  
papers

3,891  
citations

201674

27  
h-index

144013

57  
g-index

65  
all docs

65  
docs citations

65  
times ranked

6860  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotype and Genotype of Pancreatic Cancer Cell Lines. <i>Pancreas</i> , 2010, 39, 425-435.	1.1	746
2	Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. <i>Cancer Cell</i> , 2011, 19, 441-455.	16.8	452
3	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	4.9	307
4	Early Detection of Sporadic Pancreatic Cancer. <i>Pancreas</i> , 2015, 44, 693-712.	1.1	255
5	Screening for Pancreatic Cancer. <i>Annals of Surgery</i> , 2013, 257, 17-26.	4.2	217
6	The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. <i>Nature Cell Biology</i> , 2014, 16, 255-267.	10.3	172
7	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , 2019, 10, 254.	12.8	120
8	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266.	6.3	116
9	Trophic effect of amniotic fluid on fetal gastrointestinal development. <i>Journal of Surgical Research</i> , 1986, 40, 291-296.	1.6	115
10	ACS-NSQIP has the potential to create an HPB-NSQIP option. <i>Hpb</i> , 2009, 11, 405-413.	0.3	108
11	Value Driven Outcomes (VDO): a pragmatic, modular, and extensible software framework for understanding and improving health care costs and outcomes. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 223-235.	4.4	95
12	Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. <i>Analyst, The</i> , 2013, 138, 410-416.	3.5	87
13	Serum Osteopontin and Tissue Inhibitor of Metalloproteinase 1 as Diagnostic and Prognostic Biomarkers for Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2013, 42, 193-197.	1.1	86
14	Biomarkers in pancreatic adenocarcinoma: current perspectives. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7459-7467.	2.0	72
15	Defective apical extrusion signaling contributes to aggressive tumor hallmarks. <i>ELife</i> , 2015, 4, e04069.	6.0	59
16	Neuroendocrine design of the gut. <i>American Journal of Surgery</i> , 1991, 161, 243-249.	1.8	57
17	Pancreatic Resection in Veterans Affairs and Selected University Medical Centers: Results of the Patient Safety in Surgery Study. <i>Journal of the American College of Surgeons</i> , 2007, 204, 1252-1260.	0.5	56
18	Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2605-2610.	2.5	55

#	ARTICLE	IF	CITATIONS
19	Improved Diagnosis of Pancreatic Adenocarcinoma Using Haptoglobin and Serum Amyloid A in a Panel Screen. <i>World Journal of Surgery</i> , 2009, 33, 716-722.	1.6	51
20	Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. <i>Hpb</i> , 2014, 16, 670-676.	0.3	48
21	Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. <i>Surgery</i> , 2019, 165, 751-759.	1.9	43
22	Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?. <i>Surgery</i> , 2018, 164, 1178-1184.	1.9	39
23	Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. <i>Annals of Surgical Oncology</i> , 2020, 27, 333-341.	1.5	38
24	Somatostatin inhibits pancreatic exocrine secretion via a neural mechanism. <i>Metabolism: Clinical and Experimental</i> , 1990, 39, 143-148.	3.4	31
25	The Effect of Somatostatin on Experimental Intestinal Obstruction. <i>Annals of Surgery</i> , 1988, 207, 169-173.	4.2	30
26	Laparoscopic Splenectomy. <i>World Journal of Surgery</i> , 1999, 23, 384-388.	1.6	30
27	Pancreatic cancer as a sentinel for hereditary cancer predisposition. <i>BMC Cancer</i> , 2018, 18, 697.	2.6	29
28	Synthetic Extracellular Matrix Enhances Tumor Growth and Metastasis in an Orthotopic Mouse Model of Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1074-1080.	1.7	28
29	Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1813-1821.	1.7	21
30	Screening for Pancreatic Cancer. <i>Advances in Surgery</i> , 2014, 48, 115-136.	1.3	20
31	A Population-Based Description of Familial Clustering of Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 812-816.	4.4	19
32	Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells. <i>Journal of Surgical Research</i> , 1989, 46, 327-329.	1.6	18
33	Development of a Dedicated Hepatopancreaticobiliary Program in a University Hospital System. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 891-895.	1.7	16
34	Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. <i>Theoretical Biology and Medical Modelling</i> , 2014, 11, 34.	2.1	16
35	Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 133-142.	4.2	15
36	Hepatocyte Growth Factor Stimulates Fetal Gastric Epithelial Cell Growth in Vitro. <i>Journal of Surgical Research</i> , 1998, 78, 161-168.	1.6	14

#	ARTICLE	IF	CITATIONS
37	The benefits of a dedicated minimally invasive surgery program to academic general surgery practice. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 869-873.	1.7	14
38	Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. <i>Surgery</i> , 2018, 163, 753-760.	1.9	14
39	Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 1129.	7.1	14
40	Hospital Costs Following Surgical Complications. <i>Annals of Surgery</i> , 2022, 275, e375-e381.	4.2	14
41	Pyloroplasty in infancy and childhood. <i>Journal of Pediatric Surgery</i> , 1983, 18, 930-936.	1.6	13
42	Percutaneous Management of Abscess and Fistula Following Pancreaticoduodenectomy. <i>CardioVascular and Interventional Radiology</i> , 1999, 22, 25-28.	2.0	13
43	Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2010, 12, 352-358.	0.3	13
44	Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. <i>Surgery</i> , 2017, 162, 104-111.	1.9	13
45	Prognostic Factors in Pancreatic Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 1997, 6, 533-554.	1.5	12
46	Natural History of Pancreatic Cancer Recurrence Following "Curative" Resection in Athymic Mice. <i>Journal of Surgical Research</i> , 2008, 149, 57-61.	1.6	12
47	Improvement in survival of mice with proximal small bowel obstruction treated with octreotide. <i>American Journal of Surgery</i> , 1992, 163, 231-233.	1.8	11
48	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. <i>Clinical Cancer Research</i> , 2022, 28, 1938-1947.	7.0	11
49	County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 272, 1102-1109.	4.2	9
50	Surgical management of gallstone disease and postoperative complications. <i>Seminars in Gastrointestinal Disease</i> , 2003, 14, 237-44.	0.8	8
51	Perioperative Use of Octreotide in Gastrointestinal Surgery. <i>Digestion</i> , 1993, 54, 33-37.	2.3	7
52	Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1401-1413.	1.7	7
53	Selective Release of Somatostatin by Calcitonin Gene-Related Peptide and Influence on Pancreatic Secretion. <i>Annals of the New York Academy of Sciences</i> , 1992, 657, 289-298.	3.8	6
54	Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. <i>Neoplasia</i> , 2021, 23, 859-869.	5.3	6

#	ARTICLE	IF	CITATIONS
55	Value Analysis of Methods of Inguinal Hernia Repair. <i>Annals of Surgery</i> , 2021, 274, 572-580.	4.2	5
56	Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. <i>Journal of Pancreatic Cancer</i> , 2019, 5, 22-25.	0.9	4
57	A nomogram to predict pathologic lymph node positivity in clinical stage I-II pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 382-382.	1.6	1
58	Surgery for Peptic Ulcer Disease and Postgastrectomy Syndromes. , 0, , 276-282.		1
59	Surgical Approach to Functional Bowel Disease. , 1989, , 335-355.		0